Advancing CGT Trial Ecosystems in the Asia-Pacific Region

Life Sciences, Clinical Trials, Drug Discovery & Development, Cell and Gene Therapy,
  • Tuesday, May 28, 2024

As the frontiers of multi-disciplined scientific arena, cell and gene therapy (CGT) is unlocking its potential in treating those incurable illness, thus changing the life of patients. While fueled with momentum of investment opportunities, challenges in clinical operations and market access are posed in front of Asia Pacific region located biotech companies.

In this webinar, the attendees will get an in-depth understanding of the opportunities of CGT product development and market entry strategies in this fast-evolving industry. Attendees will investigate the prospectus of operational excellence, investigator engagement as well as patient recruitment on accelerating the journey, while explore Fortrea’s solution in navigating the complexity of clinical studies in CGT and share the best practices in supporting the success of both emerging biotech and large pharmaceutical sponsors.

In addition to the online presentations, feel free to book a seat in actual site of Seoul, Korea or Singapore to join face to face discussion with Fortrea experts as well as key stakeholders covering CGT ecosystem. Share the insights from various facets on advancing CGT clinical development in Asia Pacific.

Register for this webinar today to understand the opportunities of the CGT trial ecosystem and market entry strategies for biotech companies located in the Asia-Pacific region. Participants can also book a seat to attend on-site in Seoul, Korea or Singapore on May 28 to see the live presentation and meet with Fortrea experts (information will be provided upon registering for the webinar).


Frederick Derosier,

Frederick Derosier, Vice President, Therapeutic Strategy, Clinical Lead for Enterprise Cell and Gene Therapy, Fortrea

Frederick Derosier provides medical/scientific executive leadership for rare diseases and advanced therapeutics (cell, gene and RNA) at Fortrea. He joined Fortrea (Covance Inc.) in mid-2017 after pursuing 10 years of private practice (Board Certified Internal Medicine). He has 22 years of pharmaceutical/biotech clinical development experience, primarily focused in neurosciences and rare diseases.

Frederick has drug development experience across a variety of platforms, including small molecules, combination products, antibodies, neurotoxins, antisense oligonucleotides and gene therapy, and has employed a variety of delivery modalities. He has broad clinical development experience from Phase I – IV through life-cycle management. This experience encompasses clinical development planning and strategy, pediatric investigational plans (PIP) and registries and clinical strategy and oversight across program regulatory documents for the US FDA, European Medicines Agency (EMA) and Japanese Regulatory Agency (PMDA).

Message Presenter
Dong Yang, Fortrea China

Dong Yang, Head of Regulatory, Fortrea China

Dong Yang is the Head of Regulatory Affairs at Fortrea China and has over 17 years of professional experience in drug development to support IND/NDA-enabling projects and regulatory affairs.

As a board-certified Regulatory Affairs Professional (RAC global), Dong leads the regulatory relevant activities and provides strategic regulatory input for internal and external customers, including performing gap analysis and working with clients and regulatory agencies in the organization and preparation of clinical development plans, agency interactions/consultation and KOL engagements, IND and NDA applications, HGRAC submissions and CIQ applications.

Message Presenter
Dr. Jennifer Hollands, Cell Therapies (Subsidiary of Peter MacCallum Cancer Centre)

Dr. Jennifer Hollands, Government and Academic Liaison, Cell Therapies (Subsidiary of Peter MacCallum Cancer Centre)

Dr Jennifer Hollands is Cell Therapies’ Government and Academic Liaison and is responsible for all collaborations with Australian agencies, medical research institutes and researchers. Jennifer has over 15 years’ experience in regenerative medicine research as a stem cell biologist, with a major focus on the development of cell replacement therapies for neurodegenerative diseases.

Within Cell Therapies Pty Ltd, an advanced cell and gene-based therapies CDMO located in Peter MacCallum Cancer Centre, Jennifer’s role is to support the translation of pre-clinical research to early-phase clinical trials. Notably, Peter Mac is one of the leading institutions in cancer immunotherapy research, located in Australia’s premier Biomedical Precinct in Parkville, Melbourne.

Message Presenter

Eytan Abraham, VP, Business Head of Cell, Gene and Nucleic Acids Franchises, Resilience

Eytan Abraham is an experienced scientist and business leader with expertise in basic and applied biological and cell therapy R&D as well as in management, technology, and commercialization. He has an interdisciplinary background which consists of biological research, biomedical engineering, commercialization, management, and bio manufacturing, inspires passion towards being an instrumental team player in bringing novel life-saving therapies from bench-to-bedside.

Message Presenter
Ritu Singla, Fortrea

Ritu Singla, Project Manager, Fortrea

Ritu Singla is a pharmaceutical professional with over 15 years of experience in research and project management. She has experience in the full drug discovery cycle from concept stage to Phase I-III clinical trial to launch of products in therapeutic areas of hematology and oncology (including immunotherapy across multiple geographies). In her current role and her previous roles at different pharmaceutical companies such as Cell Therapies, Sienna Cancer Diagnostics, Starpharma and CSL, she has demonstrated a history of successful delivery of tangible outcomes, building global teams, managing high-profile client relationships, negotiating deals and effective strategy implementation and key stakeholder management in complex, multi-disciplinary environments. She holds a PhD and MBA from the University of Melbourne.

Message Presenter

Who Should Attend?

This webinar will be useful for bio/pharmaceutical professionals working in the following areas:

  • Cell and gene therapy: Industry contributors with an interest in cell, gene and advanced therapies
  • Trial optimization: Anyone working on trial design and optimization for the latest models including patient-centric design
  • Investigator site relations: Investigators and all stakeholders responsible for identifying and working with sites

What You Will Learn

Attendees will learn about:

  • The evolving regulatory framework for CGT in USA as well as major CGT market in the APAC regions
  • Navigating the complexity in CGT studies, leveraging resources on hospital infrastructure, clinicians as well as chain logistics to ease the burden of investigators and sites
  • Fortrea’s dedicated infrastructure and expertise in the CGT arena

Xtalks Partner


Fortrea is a leading global provider of clinical development and patient access solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients in need. Fortrea provides phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions and post-approval services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas. Our talented and diverse team of more than 19,000 people working in more than 90 countries is scaled to deliver focused and agile solutions to customers globally.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account